Anti-CD38 monoclonal antibodies have demonstrated rapid responses in immune thrombocytopenia, with response rates across several agents ranging from moderate to high. However, the durability of these responses after treatment discontinuation appears to vary. The therapeutic effects of anti-CD38 antibodies likely extend beyond depletion of CD38+ plasma cells and may involve broader modulation of the immune system.
Ghanima et al. (Thu,) studied this question.